EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Secretory IgA Is a Key Marker Among Gut Barrier Dysfunction‐Related Immunoglobulins Predicting Outcomes in ACLF

Boglarka Balogh, David Tornai iD, Aniko Csillag, Istvan Tornai, Zsuzsanna Vitalis, Patricia Kovats, Peter Antal-Szalmas, Tamas Dinya, Wim Laleman, Minneke J Coenraad, Jonel Trebicka iD, Maria Papp und 1 weitere

Liver International · 2025-10 · 45 (10)

DOI: 10.1111/liv.70350 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 13.09.2025. Verfasst von Boglarka Balogh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. Hauptthemen laut MEDLINE: Immunoglobulin A, Secretory, Intestinal Mucosa, Acute-On-Chronic Liver Failure. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, Horizon 2020, Magyar Tudományos Akadémia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims In cirrhosis, impaired gut mucosal immunity facilitates bacterial translocation (BT) instigating the proinflammatory cascade that exacerbates hepatic damage. The role of antibody‐mediated immunity in this process remains unclear. We assessed serum immunoglobulins (Ig) linked to gut barrier function as prognostic markers in a prospective MICROB‐PREDICT cohort of patients with acutely decompensated (AD) cirrhosis.

Methods

Serum samples of 128 patients were assayed for IgA and IgG antibodies against various targets (filamentous‐actin; Saccharomyces cerevisiae [ASCA]; glycoprotein‐2 [GP2]; gliadin; endotoxin‐core [EndoCab]), secretory (s)IgA, total‐IgA, IgG, IgM and free Ig kappa/lambda light chains. Mortality was assessed during a 3‐month follow‐up period. An independent ACLF patient cohort ( n = 50) was used to validate sIgA‐related findings.

Results

IgA ‐type target‐specific antibodies were more prevalent than IgG types. Target‐specific antibody diversity and concentrations, total‐ IgA levels and Child–Pugh severity exhibited concordant elevations. Total‐ IgG levels were inversely associated with CLIF ‐C AD score and presence of ACLF . sIgA levels increased in parallel with ACLF grades. Elevated sIgA levels were associated with 90‐day mortality in ACLF patients ( n = 37; AUROC : 0.859; at the cut‐off of > 20.9 μg/ mL : 11.1% vs. 78.9% Mortality p < 0.001). These findings were confirmed in the validation cohort. In the merged ACLF cohort ( n = 87), high sIgA levels predicted 90‐day mortality independent of CLIF ‐C ACLF score ( HR : 3.367; CI : 1.563–7.225; p = 0.002).

Conclusion

Enhanced BT‐triggered immune activation is indicated by increased total‐IgA levels in association with the occurrence of target‐specific IgA antibodies. Serum sIgA is a promising marker of gut barrier failure and 90‐day mortality in ACLF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin A, SecretoryIntestinal MucosaAcute-On-Chronic Liver FailureHumansMaleFemaleMiddle AgedBiomarkersProspective StudiesImmunoglobulin GPrognosisAgedAdultImmunity, MucosalBacterial Translocation

Stichwörter der Autor:innen

acute‐on‐chronic liver failureadaptive immunitygut barrier failureimmunoglobulin Asecretory IgAshort‐term mortality

Substanzen

Immunoglobulin A, SecretoryBiomarkersImmunoglobulin G

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Kalman Laki Doctoral School of Biomedical and Clinical Sciences, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Department of Surgery, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Department of Gastroenterology & Hepatology, Division of Liver & Biliopancreatic Disorders and Liver Transplantation, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
  • Department of Internal Medicine B, University of Münster, Münster, Germany.

ORCID-Profile: David Tornai, Jonel Trebicka

Förderung

  • Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund
  • Horizon 2020
  • Magyar Tudományos Akadémia
  • Ministry for Culture and Innovation of Hungary from the source of the National Research, Development and Innovation Fund
  • Horizon 2020 Framework Programme

Zitieren

APA

Balogh, B., Tornai, D., Csillag, A., Tornai, I., Vitalis, Z., Kovats, P., Antal-Szalmas, P., Dinya, T., Laleman, W., Coenraad, M. J., Trebicka, J., Papp, M., & MICROB‐PREDICT and PREDICT study group of the EASL‐CLIF consortium (2025). Secretory IgA Is a Key Marker Among Gut Barrier Dysfunction‐Related Immunoglobulins Predicting Outcomes in ACLF. Liver International, 45(10). https://doi.org/10.1111/liv.70350

Vancouver

Balogh B, Tornai D, Csillag A, Tornai I, Vitalis Z, Kovats P, et al. Secretory IgA Is a Key Marker Among Gut Barrier Dysfunction‐Related Immunoglobulins Predicting Outcomes in ACLF. Liver International. 2025;45(10). doi:10.1111/liv.70350

BibTeX
@article{Balogh2025,
  author = {Balogh, Boglarka and Tornai, David and Csillag, Aniko and Tornai, Istvan and Vitalis, Zsuzsanna and Kovats, Patricia and Antal-Szalmas, Peter and Dinya, Tamas and Laleman, Wim and Coenraad, Minneke J and Trebicka, Jonel and Papp, Maria and MICROB‐PREDICT and PREDICT study group of the EASL‐CLIF consortium, MICROB‐PREDICT and PREDICT study group of the EASL‐CLIF consortium},
  title = {Secretory IgA Is a Key Marker Among Gut Barrier Dysfunction‐Related Immunoglobulins Predicting Outcomes in ACLF},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {10},
  doi = {10.1111/liv.70350}
}
Kostenlos starten →